ClinicalTrials.gg
CompletedNCT06923566Updated Apr 11, 2025

Targeted Muscle Reinnervation in the Hand for the Managment of Symptomatic Neuroma Following Digit and Hand Amputations

An interventional study of Targeted muscle reinnervation in Targeted Muscle Reinervation, Digital Amputation and Neuroma, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Aug 2021, registered Mar 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Neuromas are a common complication after digital and hand amputations, resulting in significant pain, discomfort, and functional impairment. Various management methods are available, including surgical excision, nerve blocks, and nerve stump protectors, but these treatments may have limited success rates and potential complications. Targeted muscle reinnervation (TMR) is a promising technique that involves surgically rerouting a severed nerve into a nearby muscle, which can prevent the formation of neuromas and provide improved muscle function

02

Conditions studied

  • Targeted Muscle Reinervation
  • Digital Amputation
  • Neuroma

Browse trials for

Keywords

  • Targeted muscle reinnervation
  • neuroma
  • amputation
03

In context

Neuroma

71 studies on the registry are indexed under Neuroma; 9 are open to participants now.

This study's enrollment of 17 is below the median of 32 across 50 interventional studies indexed under Neuroma.

Browse Neuroma studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,932 studies on the registry; 433 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Arabic or English speaking individuals
  • An upper limb amputation distal to the wrist crease
  • A symptomatic neuroma within the hand or digits: defined as patient-reported localized pain consistent with a clinical exam of a neuroma pain.There must be a supporting Tinel's sign on physical exam.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment for better assessment of patient reported outcomes and filling questionnaires and signing consents
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    targeted muscle reinervation post digit amputation group

    In 1ry TMR ,after the amputation is performed by the standard method , transected nerves will be replanted micro surgically to motor entry points (MEPS)in the hand as predetermined by Daugherty et al , Motor branches in the recipient muscles could be determined by a nerve stimulator intraoperatively. In 2ry TMR , neuroma site will be explored and it will be excised ,the distal end of the transected nerve will be connected micro surgically to the nearest MEPS

    Procedure: Targeted muscle reinnervation

Interventions

  • ProcedureTargeted muscle reinnervation

    In 1ry TMR ,after the amputation is performed by the standard method , transected nerves will be replanted micro surgically to motor entry points (MEPS)in the hand as predetermined by Daugherty et al , Motor branches in the recipient muscles could be determined by a nerve stimulator intraoperatively. In 2ry TMR , neuroma site will be explored and it will be excised ,the distal end of the transected nerve will be connected micro surgically to the nearest MEPS

06

What researchers measure

Primary outcomes

  1. Neuroma incidence

    Neuroma incidence post TMR operation is recorded via Tinel's sign

    Time frame: through study completion, an average of 1 year

  2. Neuroma recurrence

    Neuroma recurrence in cases of 2ry TMR cases

    Time frame: through study completion, an average of 1 year

  3. Pain intensity

    measured using pain rating numerical scale commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable

    Time frame: will be taken at intervals over time (1 month, 3 months,6 months, 9 months,1 year until the conclusion of the study

  4. Pain medication usage type

    pain medication usage type recorded

    Time frame: Followed up at intervals over time (1 month, 3 months,6 months, 9 months,1 year until the conclusion of the study

  5. Pain medication usage frequency

    pain medication usage frequency recorded

    Time frame: Followed up at intervals over time (1 month, 3 months,6 months, 9 months,1 year until the conclusion of the study

  6. Pain character

    Leeds Assessment of neuropathic symptoms and signs pain scale is a valuable tool designed to evaluate and categorize pain. Its primary purpose is to determine if nerve damage is the primary cause of the pain, distinguishing between neuropathic and nociceptive pain. The scale comprises seven items, divided into two sections. The first part consists of five questions related to symptoms experienced by the individual. The second part involves two clinical examination items that are typically conducted in collaboration with a healthcare provider. A score of 12 or more on this scale confirms a diagnosis of neuropathic pain to some degree. Scores below 12 are less likely to show neuropathic pain

    Time frame: will be taken at intervals over time (1 month, 3 months,6 months, 9 months,1 year until the conclusion of the study

  7. Pain character

    The McGill Pain Questionnaire is a well-known assessment tool used to quantify and understand the subjective experience of pain. It primarily consists of three major categories of word descriptors-sensory affective, and evaluative-through which patients can express and specify their pain experience. In addition to these descriptors, the questionnaire includes an intensity scale and other items to further capture the properties of the pain being experienced.

    Time frame: will be taken at intervals over time (1 month, 3 months,6 months, 9 months,1 year until the conclusion of the study

Secondary outcomes

  1. operative time

    measuring the operative time

    Time frame: intraoperative

  2. Rate of infection

    surgical site infections were recorded

    Time frame: up to 30 days postoperative

07

Study locations

1 site
  • Ain Shams University Faculty of medicine
    Al ‘Abbāsīyah, Cairo Governorate 11655, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923566
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Aug 20, 2021
Primary completion
Jul 30, 2023
Completion
Sep 2, 2023
Last update
Apr 11, 2025

Study contacts

Ayman Ibrahim Fathy Aly Howeidy, Professor
study chair · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion